Management of Dyslipidemia
1. Risk Stratification (Foundation)
Management is driven by overall cardiovascular risk rather than LDL alone
Major risk categories:
Established ASCVD (very high risk)
Diabetes mellitus
Severe hypercholesterolemia (LDL ≥190 mg/dL)
Primary prevention based on risk calculators
---
2. Lifestyle Modification (First-line for all)
Diet
Reduce saturated & trans fats
Increase fiber (fruits, vegetables, whole grains)
Mediterranean/DASH-style diet
Limit refined sugars
Exercise
≥150 min/week moderate intensity
Weight
Target BMI <25 kg/m²
Others
Smoking cessation
Limit alcohol
---
3. Pharmacologic Therapy
A. Statins (First-line)
↓ LDL by 30–60%
Stabilize plaques
High-intensity statins
Atorvastatin 40–80 mg
Rosuvastatin 20–40 mg
Indications
ASCVD → high-intensity
LDL ≥190 → high-intensity
Diabetes (age 40–75) → moderate/high
---
B. Non-Statin Therapies
Ezetimibe
Add if LDL target not achieved with statin
PCSK9 inhibitors
Alirocumab, Evolocumab
For very high-risk or statin intolerance
Bempedoic acid
Alternative in statin intolerance
---
C. Hypertriglyceridemia Treatment
TG 150–499 mg/dL
Lifestyle + statins
TG ≥500 mg/dL (pancreatitis risk)
Fibrates (Fenofibrate)
Omega-3 fatty acids
---
4. LDL Targets (Guideline-Oriented)
Very high risk: <55 mg/dL
High risk: <70 mg/dL
Moderate risk: <100 mg/dL
---
5. Special Situations
Diabetes
Statin for all ≥40 years
Chronic kidney disease
Statin ± ezetimibe
Statin intolerance
Try lower dose / alternate statin
Add non-statin agents
---
6. Monitoring
Lipid profile: baseline, then 4–12 weeks after therapy
Liver enzymes (if indicated)
CK (only if muscle symptoms)
---
7. Key Takeaways
Lifestyle + statin = cornerstone
Treat risk, not just numbers
Add ezetimibe → PCSK9 if targets unmet
Treat high triglycerides to prevent pancreatitis
---
Drmusmanjaved.com

Comments
Post a Comment
Drop your thoughts here, we would love to hear from you